Xiaoqiong Wu

Xiaoqiong Wu

Auto-generated profile, based on publicly available information

Xiaoqiong Wu

School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2019 in Cancer Biology & Therapy
Verified
Journal Article
Open access
YZYining Zhao
Yining Zhao
YLYumei Li
Yumei Li
XWXiaoqiong Wu
Xiaoqiong Wu
LLLi Li
Li Li
JLJiayu Liu
Jiayu Liu
ZWZhong Wang
Zhong Wang
CD16a (FcγRIIIa) mediates the antibody dependent cellular cytotoxicity (ADCC) and is important for anti-tumor activities of many therapeutic antibodies. Bispecific antibody targeting natural killer (NK) cells has been studied for cancer therapy. In this work, anti-CD16a single-domain antibodies were identified from hCD16a immunized camel. Bispecific antibodies are then constructed by fusing these single domain antibodies with an anti-CEA single domain antibody. These bispecific antibodies can recruite NK cells to kill CEA-positive tumor cells, and inhibit tumor growth in vivo, suggesting that these anti-CD16a single domain antibodies are powerful tools to engaging NK cells for cancer therapy.

1 April 2018 in Translational Oncology
Verified
Journal Article
Open access
XWXiaoqiong Wu
Xiaoqiong Wu
SCSiqi Chen
Siqi Chen
LLLimin Lin
Limin Lin
JLJiayu Liu
Jiayu Liu
YWYanlan Wang
Yanlan Wang
ZWZhong Wang
Zhong Wang
Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% to 30% of breast cancers and various other types of cancers, which plays a vital role in the cancer progression. Monoclonal antibodies targeting Her2 are now used in the clinic to treat Her2 overexpression cancer patients. However, relapse or resistance is frequent with the current therapies. To generate a new treatment avenue against Her2, we immunized and selected a specific anti-Her2 single domain antibody C3 for further studies. The C3-Fc antibody drove antibody-dependent cell-mediated cytotoxicity against Her2-positive tumor cells in vitro and resulted in potent antitumor growth in vivo. These data suggest that the C3-Fc antibody may provide an alternative avenue for Her2-positive cancer therapy.